scholarly journals No decrease of the beta-cell mass in type 2 diabetic patients

Diabetes ◽  
2001 ◽  
Vol 50 (Supplement 1) ◽  
pp. S188-S188 ◽  
Author(s):  
Y. Guiot ◽  
C. Sempoux ◽  
P. Moulin ◽  
J. Rahier
Keyword(s):  
Beta Cell ◽  
Cell Mass ◽  
Beta Cell Mass ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

scholarly journals Islet cell and glutamic acid decarboxylase-65 autoantibodies in young diabetic patients attending in a General Hospital in Dhaka City

2020 ◽  
Vol 46 (2) ◽  
pp. 104-108
Author(s):  
Ashesh Kumar Chowdhury ◽  
Shahjalalur Rahman Sahi ◽  
Mohammad Moniruzzaman ◽  
Mansura Khan
Keyword(s):  
Beta Cell ◽  
Diabetic Control ◽  
Acid Decarboxylase ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Significant Difference ◽  
Gad 65 ◽  
Glutamic Acid Decarboxylase 65 ◽  
Type 2 Diabetic

Background: Immune mediated destruction of pancreatic beta cell in type-I diabetes is well established but its’ role in young type-2 diabetic patients is still not conclusive. These young diabetic patients pass through several stages where they do not need insulin but found to have serum autoantibody against islets cell and even become dependent on insulin for survival in course of time. This study aims to find the presence of islets cell auto-antibodies (ICA) and autoantibody to glutamic acid decarboxylase-65 (GAD-65) in non-insulin requiring young diabetic patients of Bangladesh. Objective: To evaluate the presence of ICA and GAD-65 between the non-insulin requiring young type-2 diabetic patients and compare with the non-diabetic control group. Method: This case control study was carried out at the Department of Immunology, BIRDEM General Hospital, Dhaka for a period of one year from July 2013, A total of 120 non-insulin requiring (≥12 months) young type-2 diabetic patients and 60 age, sex matched non-diabetic were enrolled as control subjects following inclusion and exclusion criteria. ICA and GAD-65 tests were performed by enzyme linked immune-sorbent assay (ELISA) method by using kits from DRG Inc. International, USA. Results: In this study statistically significant difference found between non insulin requiring young diabetic patients and non diabetic control in respect of positive ICA result (p=0.015). The moderately strong negative association was found between different age of onset of diabetes mellitus and value of ICA level (r=-0.45). Only 20-24 years age group showed statistically significant difference between patient and control (p=0.013). Statistically significant difference was not found in GAD-65 values of non insulin requiring young diabetic patients and non diabetic controls (p=0.441). Conclusion: This study revealed that there is significant difference present in respect of ICA among non-insulin requiring young diabetic patients and non-diabetic controls. Therefore, autoimmune pathogenesis of beta cell killing by producing ICA against islets cell take place in young type-2 diabetic patients. Bangladesh Med Res Counc Bull 2020; 46(2): 104-108

Adverse Impact of Hashimoto's Thyroiditis on Pancreatic Beta-Cell Function in Type 2 Diabetic Patients

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2129-P ◽  
Author(s):  
YUANYUAN ZHANG ◽  
RONGXIN SUN ◽  
LIJIE ZHANG ◽  
YUAN FANG ◽  
CAIGUO YU ◽  
...  
Keyword(s):  
Beta Cell ◽  
Beta Cell Function ◽  
Cell Function ◽  
Pancreatic Beta Cell ◽  
Adverse Impact ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Pancreatic Beta Cell Function ◽  
Type 2 Diabetic

Quantification of the pancreatic beta-cell mass and insulin content in normal and type 2 diabetic subjects in Korea

2000 ◽  
Vol 50 ◽  
pp. 144-145
Author(s):  
Ho-Young Son ◽  
Kun-Ho Yoon ◽  
Seung-Hyun Ko ◽  
Sun-Hee Seo ◽  
Sung-Dae Moon ◽  
...  
Keyword(s):  
Beta Cell ◽  
Pancreatic Beta Cell ◽  
Cell Mass ◽  
Beta Cell Mass ◽  
Insulin Content ◽  
Pancreatic Beta Cell Mass ◽  
Type 2 Diabetic

scholarly journals Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients

2019 ◽  
Vol 11 (1) ◽  
Author(s):  
Meng-jie Tang ◽  
Jian‑bin Su ◽  
Tian-li Xu ◽  
Xue‑qin Wang ◽  
Dong-mei Zhang ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Beta Cell ◽  
Beta Cell Function ◽  
Cell Function ◽  
Diabetic Patients ◽  
Fibroblast Growth ◽  
Type 2 Diabetic Patients ◽  
Fibroblast Growth Factor 19 ◽  
Type 2 Diabetic

Abstract Background Fibroblast growth factor 19 (FGF19) takes part in maintaining the balance of glycolipids and may be involved in regulating the secretory activity of islet beta cells in patients with type 2 diabetes. This study aimed to evaluate the relationship between the levels of serum FGF19 and endogenous islet beta cell function in type 2 diabetic patients. Methods Samples were obtained from 271 subjects: 85 drug-naïve type 2 diabetes participants exclusively on lifestyle intervention (N-DM group), 122 type 2 diabetes subjects previously used medications (DM group) and 64 normal controls (NC group). Serum FGF19 concentrations were measured by ELISA. The insulin sensitivity (MI), insulin secretion (AUCins/AUCglu) and insulin secretion-sensitivity index-2 (ISSI-2) were also measured in the N-DM and DM. Results Serum FGF19 levels decreased, in order, from the NC group [median (interquartile range), 245.03 (126.23–317.43) pg/mL] to the N-DM group [170.05 (89.01–244.70) pg/mL] and, finally, to the DM group [142.25 (55.55–187.58) pg/mL] (p for trend < 0.05). Among subjects in the DM group, there was a positive trend in the serum FGF19 concentration; plasma insulin levels at 60 min, 120 min (INS60, INS120, respectively); and area under the insulin curve (AUCins) at two points (r = 0.214, p = 0.025; r = 0.189, p = 0.048; r = 0.188, p = 0.049). However, the differences were no longer observed among the N-DM subjects. Simultaneously, the ISSI-2 was closely related to the serum FGF19 levels (r = 0.297, p = 0.002) among DM subjects. Furthermore, after adjusting for age, sex, duration, therapy and other clinical factors via multiple logistic regression analysis, ISSI-2 was a key independent factor in the levels of FGF19 (β = 0.281, t = 2.557, p = 0.013). Conclusions The serum FGF19 level has a close relation with endogenous beta cell function among DM subjects, as assessed by the ISSI-2. As ISSI-2 is higher in N-DM group, FGF19 may be a main protector in dysfunction of beta cell.

Sign in / Sign up

Export Citation Format

Share Document